August 1, 2024Cell Death and DiseaseOpen Access

PD-L1 induces autophagy and primary resistance to EGFR–TKIs in EGFR-mutant lung adenocarcinoma via the MAPK signaling pathway

View Full Paper

Ask AI

Bookmark

Authors

NLNa Li RZRan Zuo YHYuchao He

Discussion

Member takes

Overview

Preclinical study reveals that PD-L1 promotes EGFR-TKI resistance through MAPK-induced autophagy in EGFR-mutant lung adenocarcinoma, highlighting combination therapy benefits.

Key Points

Upregulation of PD-L1 promotes primary resistance to EGFR-TKIs in lung adenocarcinoma cells, and it accelerates tumor proliferation while suppressing cellular apoptosis.
Approximately 30% of EGFR-mutant cases exhibit primary resistance, but combining gefitinib with pemetrexed synergistically restores therapeutic antitumor efficacy.
In vitro and in vivo experiments demonstrate that PD-L1 induces autophagy via MAPK signaling, highlighting a therapeutic target—preclinical model; clinical trials needed.

Cite This Study

Li et al. (2024) studied this question.

synapsesocial.com/papers/68e5dc44b6db6435875717c6 https://doi.org/10.1038/s41419-024-06945-7

View Full Paper

Ask AI

Bookmark

August 1, 2024Cell Death and DiseaseOpen Access

PD-L1 induces autophagy and primary resistance to EGFR–TKIs in EGFR-mutant lung adenocarcinoma via the MAPK signaling pathway

View Full Paper

Ask AI

Bookmark

Authors

NLNa Li RZRan Zuo YHYuchao He

Discussion

Member takes

Overview

Preclinical study reveals that PD-L1 promotes EGFR-TKI resistance through MAPK-induced autophagy in EGFR-mutant lung adenocarcinoma, highlighting combination therapy benefits.

Key Points

Upregulation of PD-L1 promotes primary resistance to EGFR-TKIs in lung adenocarcinoma cells, and it accelerates tumor proliferation while suppressing cellular apoptosis.
Approximately 30% of EGFR-mutant cases exhibit primary resistance, but combining gefitinib with pemetrexed synergistically restores therapeutic antitumor efficacy.
In vitro and in vivo experiments demonstrate that PD-L1 induces autophagy via MAPK signaling, highlighting a therapeutic target—preclinical model; clinical trials needed.

Cite This Study

Li et al. (2024) studied this question.

synapsesocial.com/papers/68e5dc44b6db6435875717c6 https://doi.org/10.1038/s41419-024-06945-7

Also Consider

Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark